Carregant...
Emerging therapies in advanced hepatocellular carcinoma
BACKGROUND: Prognosis is very poor for advanced HCC patients partially due to lack of effective systemic treatment. Sorafenib was the only approved agent for advanced HCC since 2007 until recent breakthroughs. In this article, we will review the newer approved and promising agents in the treatment o...
Guardat en:
| Publicat a: | Exp Hematol Oncol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6076403/ https://ncbi.nlm.nih.gov/pubmed/30087805 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0109-6 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|